Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. (ITCI) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
itci · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Intra-Cellular Therapies, Inc. (ITCI) measures how much investors pay for each dollar of the company's trailing earnings. ITCI's current PE ratio of N/A is calculated by dividing its stock price of $131.87 by its TTM earnings per share of -$0.72.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2013 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Intra-Cellular Therapies, Inc.You ITCI | $14.0B | N/A | — | -$0.72 |
 Abiomed, Inc. ABMD | $17.2B | 110.28x | +62.9% | $3.00 |
 Becton, Dickinson and Company BDX | $54.4B | 25.13x | -62.9% | $5.85 |
 Catalent, Inc. CTLT | $11.5B | N/A | — | -$5.76 |
 ImmunoGen, Inc. IMGN | $8.7B | N/A | — | -$0.88 |
 Karuna Therapeutics, Inc. KRTX | $12.6B | N/A | — | -$11.73 |
 Oak Street Health, Inc. OSH | $9.5B | N/A | — | -$2.21 |
Industry Average 2 peers with valid PE | — | 67.70x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-0.72 | — | |
2023-12-31 FY2023 | — | $-1.46 | — | |
2022-12-31 FY2022 | — | $-2.72 | — | |
2021-12-31 FY2021 | — | $-3.50 | — | |
2020-12-31 FY2020 | — | $-3.23 | — | |
2019-12-31 FY2019 | — | $-2.68 | — | |
2018-12-31 FY2018 | — | $-2.84 | — | |
2017-12-31 FY2017 | — | $-2.12 | — | |
2016-12-31 FY2016 | — | $-2.69 | — | |
2015-12-31 FY2015 | — | $-2.91 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Intra-Cellular Therapies, Inc. (ITCI) measures how much investors pay for each dollar of the company's trailing earnings. ITCI's current PE ratio of N/A is calculated by dividing its stock price of $131.87 by its TTM earnings per share of -$0.72.
Frequently asked questions
ITCI pe ratio · 6 questionsITCI's current PE ratio is N/A as of 2026-06-09, based on a stock price of $131.87 and TTM EPS of -$0.72. Data sourced from Financial Modeling Prep via ITCI's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Intra-Cellular Therapies, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09